1.Molecular basis of UVA-induced skin aging and arotinoid ethyl ester protection.
Zhung-yong LIU ; Guo-wei ZHANG ; Guo-fu YAN ; yong-xin LEU ; Yun-zhi HE
Chinese Journal of Industrial Hygiene and Occupational Diseases 2003;21(5):384-385
Benzoates
;
pharmacology
;
Cells, Cultured
;
Cellular Senescence
;
drug effects
;
radiation effects
;
Gene Expression Regulation, Enzymologic
;
drug effects
;
radiation effects
;
Humans
;
Infant, Newborn
;
Male
;
Matrix Metalloproteinase 1
;
genetics
;
Matrix Metalloproteinase 3
;
genetics
;
Methoxsalen
;
pharmacology
;
RNA, Messenger
;
genetics
;
metabolism
;
Retinoids
;
pharmacology
;
Skin
;
cytology
;
metabolism
;
Time Factors
;
Tissue Inhibitor of Metalloproteinases
;
metabolism
;
Ultraviolet Rays
2.Effect of high humidity environment on immune function in rats.
Xin GUO ; Kun LI ; Chao WANG ; Wei LI ; Yun YANG ; Fu-Qiang SONG ; Yong-He HU
Chinese Journal of Applied Physiology 2014;30(1):89-92
OBJECTIVETo investigate effects of the variation of immune function in high humidity environment in different time, and lay a foundation for further study of the related mechanism.
METHODThirty SD rats were divided into 3 groups (n = 10): 20 day group, 40 day group in 90% relative humidity chamber and control group in normal relative humidity. Peripheral blood and spleens were collected to detect the levels of T lymphocyte subsets by Flow Cytometery.
RESULTSIn peripheral blood of the 20 day group rats, the CD3+ %, CD4+ %, CD8+ % and CD4+/CD8+ were 52.91 +/- 6.27, 37.80 +/- 4.11, 14.85 +/- 3.73 and 2.72 +/- 0.82 separately. Expect CD3+ %, they all had significant differences (P < 0.05). In addition, the data of the 40 day group rats showed no diversity in statistics. In spleen, CD8+ % of the 20 day group rats was 6.23 +/- 2.87 with significant differences (P < 0.05) and IgG, IgA and IgM did not change a lot in blood serum of the high humidity groups except C3 of the 20 days group (P < 0.05).
CONCLUSIONIn high humidity environment, the immune function of the rats increased in the initial stage. As time went on, the immune function gradually went to normal level through the self adjustment.
Acclimatization ; Animals ; Humidity ; Rats ; Rats, Sprague-Dawley ; Spleen ; immunology ; T-Lymphocyte Subsets ; immunology
3.Anti-dementia effect of Tongluo Xingnao effervescent tablet based on urinary metabonomics.
Jiang-ping WEI ; Yin-jie ZHANG ; Yun-tong MA ; Shi-jun XU ; Yong-yan WANG
China Journal of Chinese Materia Medica 2015;40(16):3287-3292
Tongluo Xingnao effervescent tablet (TLXNET) is a patented prescription, which comes from modified Xionggui decoction and can improve cognitive function. However, its effect on the urine metabolites and anti-dementia mechanism in the dementia model rats induced by hippocampal injection with Aβ25-35 remains unclear. The experiment focused on the changes in trajectory and inter-relationship among the urinary metabolite of rats in the blank group, Aβ25-35 hippocampal injection dementia model group and the TLXNET intervention group, in order to determine theirs characteristic metabolic markers and explain the anti-dementia effect of TLX-NET base on the change of metabolic trajectory of these bio-markers. According to the experimental results, 5, 6-indolequinone, 4-hydroxyphenyl pyruvic acid (4-HPPA), cortisol and 3-thiosulfate lactic were preliminarily identified as the characteristic metabolic markers. They mainly participate in dopamine system, glucocorticoids and energy metabolic pathways. TLXNET can apparently downregulate the disturbances of metabolic trajectory of the four bio-markers. The experiment indicates that the dementia model induced by injecting Aβ25-3 into hippocampus has its characteristic endogenous metabolic markers in urine, and ELXNET can ameliorate dementia by down-regulating the disturbances of metabolic trajectory.
Amyloid beta-Peptides
;
metabolism
;
toxicity
;
Animals
;
Biomarkers
;
urine
;
Dementia
;
drug therapy
;
urine
;
Drugs, Chinese Herbal
;
administration & dosage
;
Female
;
Hippocampus
;
drug effects
;
metabolism
;
Humans
;
Male
;
Metabolomics
;
Peptide Fragments
;
metabolism
;
toxicity
;
Rats
;
Rats, Sprague-Dawley
;
Tablets
;
administration & dosage
;
Urine
;
chemistry
4.Gene mutation and mRNA expression of PUMA gene in non-small cell lung cancer.
Yu-ming WANG ; Ke-wei JIN ; Ya LI ; Yun-ru CHEN ; Yong DUAN
Chinese Journal of Pathology 2009;38(2):121-122
Adult
;
Aged
;
Aged, 80 and over
;
Apoptosis Regulatory Proteins
;
genetics
;
metabolism
;
Carcinoma, Non-Small-Cell Lung
;
genetics
;
metabolism
;
Exons
;
genetics
;
Female
;
Gene Expression Regulation, Neoplastic
;
Humans
;
Lung Diseases
;
genetics
;
metabolism
;
Lung Neoplasms
;
genetics
;
metabolism
;
Male
;
Middle Aged
;
Mutation
;
Proto-Oncogene Proteins
;
genetics
;
metabolism
;
RNA, Messenger
;
metabolism
5.Acral myxoinflammatory fibroblastic sarcoma: report of a case.
Xiao-Hui WU ; Yong-Wei YU ; Yang WANG ; Yun LIN ; Ming-Hua ZHU
Chinese Journal of Pathology 2007;36(2):139-140
Adult
;
Diagnosis, Differential
;
Foot Diseases
;
metabolism
;
pathology
;
surgery
;
Humans
;
Immunohistochemistry
;
Male
;
Myxosarcoma
;
metabolism
;
pathology
;
surgery
;
Neoplasms, Muscle Tissue
;
pathology
;
Soft Tissue Neoplasms
;
metabolism
;
pathology
;
surgery
;
Tenosynovitis
;
pathology
;
Vimentin
;
metabolism
6.Discussion about risk and management of Chinese patent medicine with double identity.
Yun JIN ; Sai-wei WU ; Xing-wang GAO ; Dan-hua XU ; Yong-song ZHAI
China Journal of Chinese Materia Medica 2015;40(11):2249-2251
Chinese patent medicine with double identity was a special phenomenon, and many preparations not only were prescription drugs but also over the counter ( OTC) drugs, which brought a lot of trouble. Based on statistics of list of OTC medicines of CFDA, related varieties, route of administration and functions of these drugs were searched. The causes of insufficient were analyzed and the potential risk was investigated. To ensure the safety of drug usage for the patient, risk management system should be set up by improving the technical requirements for registration, improving the drug labels and manuals, playing the role of pharmacists in pharmacy services and raising awareness of doctor and patient for these drugs.
China
;
Humans
;
Nonprescription Drugs
;
adverse effects
;
Risk Management
7.Simultaneous determination of clevidipine butyrate and its metabolite clevidipine acid in dog blood by liquid chromatography-tandem mass spectrometry.
Hui-hui WEI ; Yuan GU ; Yan-ping LIU ; Guang-li WEI ; Yong CHEN ; Chang-xiao LIU ; Duan-yun SI
Acta Pharmaceutica Sinica 2015;50(10):1290-1296
A rapid, sensitive and simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous determination of clevidipine butyrate and its primary metabolite clevidipine acid in dog blood. After one-step protein precipitation with methanol, the chromatographic separation was carried out on an Ecosil C18 column (150 mm x 4.6 mm, 5 µm) with a gradient mobile phase consisting of methanol and 5 mmol · L(-1) ammonium formate. A chromatographic total run time of 13.0 min was achieved. The quantitation analysis was performed using multiple reaction monitoring (MRM) at the specific ion transitions of m/z 454.1 [M-H]- --> m/z 234.1 for clevidipine butyrate, m/z 354.0 [M-H]- --> m/z 208.0 for clevidipine acid and m/z 256.1 [M-H]- --> m/z 227.1 for elofesalamide (internal standard, IS) in the negative ion mode with electrospray ionization (ESI) source. The linear calibration curves for clevidipine butyrate and clevidipine acid were obtained in the concentration ranges of 0.5-100 ng · mL and 1-200 ng · mL(-1), separately. The lower limit of quantification of clevidipine butyrate and clevidipine acid were 0.5 ng · mL(-1) and 1 ng · mL(-1). The intra and inter-assay precisions were all below 12.9%, the accuracies were all in standard ranges. Stability testing indicated that clevidipine butyrate and clevidipine acid in dog blood with the addition of denaturant methanol was stable under various processing and/or handling conditions. The validated method has been successfully applied to a pharmacokinetic study of clevidipine butyrate injection to 8 healthy Beagle dogs following intravenous infusion at a flow rate of 5 mg · h(-1) for 0.5 h.
Animals
;
Butyrates
;
blood
;
pharmacokinetics
;
Calibration
;
Chromatography, Liquid
;
Dogs
;
Infusions, Intravenous
;
Pyridines
;
blood
;
pharmacokinetics
;
Tandem Mass Spectrometry
9.Influence of intracoronary administration of anisodamine on no-reflow, ventricular function and systolic synchrony in acute myocardial infarction patients undergoing percutaneous coronary intervention.
Wei-ze FAN ; Xiang-hua FU ; Yun-fa JIANG ; Xin-shun GU ; Wei-li WU ; Shi-qiang LI ; Jun LIU ; Ling XUE ; Yong-yun WEI ; Guo-zhen HAO
Chinese Journal of Cardiology 2007;35(10):908-913
OBJECTIVETo evaluate the influence of intracoronary administration of anisodamine on myocardial blush grade (MBG) and left ventricular regional and global systolic function and synchrony in the acute myocardial infarction (AMI) patients with no-reflow phenomenon post percutaneous coronary intervention (PCI).
METHODSForty-seven AMI patients who underwent PCI within 12 hours of onset and MBG was 0 - 1 were randomized to receive standard therapy [group B, n = 23, 18 males, mean age (62.72 +/- 11.48) years] or standard therapy plus intracoronary administration of anisodamine [200 microg/ml, group A, n = 24, 18 males, mean age (64.23 +/- 12.27) years]. The left ventriculography (LVG) was performed immediately and 6 months after PCI to measure the ventricular volume, LVEDP and wall motion score (WMS). Equilibrium radionuclide angiography (ERNA) was performed 1 week and 6 months after PCI to determine the parameters of left ventricular regional, global systolic function and systolic synchrony. Incidence of major adverse cardiac events (MACE) during the follow-up was analyzed.
RESULTSAnisodamine [(2530 +/- 340) microg/person)] was well tolerated by patients. The MBG remained unchanged in group B and significantly increased from grade 0.74 +/- 0.32 to grade 2.33 +/- 0.28 10 min after anisodamine injection in group B. Six months post PCI, LVESVI [(40.53 +/- 8.12) ml/m(2) vs. (50.32 +/- 8.26) ml/m(2)], LVEDVI [(80.13 +/- 9.74) ml/m(2) vs. (87.17 +/- 10.25) ml/m(2)], WMS [(8.24 +/- 1.31) vs. (10.23 +/- 1.82)] and LVEDP [(13.36 +/- 4.21) vs. (16.38 +/- 3.21) mm Hg, 1 mm Hg = 0.133 kPa] were significantly lower in group A compared with that in group B (all P < 0.05) while LVEF [(44.02 +/- 5.86)% vs. (38.52 +/- 5.18)%], PER [(1.86 +/- 0.09) EDV/s vs. (1.61 +/- 0.09) EDV/s] and PFR [(2.19 +/- 0.32) EDV/s vs. (1.78 +/- 0.17) EDV/s] measured by ERNA were significantly increased in group A compared with that in group B (all P < 0.05). (2) LrEF(2)-LrEF(8) in group A were higher by 13.96%, 25.02%, 30.36%, 22.86%, 27.67%, 22.07% and 18.71% respectively compared with that in group B. (3) Phase analysis showed that the left ventricular systolic synchrony parameters PS [(46.04 +/- 8.93) degrees vs. (53.19 +/- 162) degrees ], FWHM [(23.02 +/- 6.27) degrees vs. (25.02 +/- 5.31) degrees ] and PSD [(7.92 +/- 4.12) degrees vs. (11.76 +/- 4.11) degrees ] were also significantly lower in group A than that in group B (all P < 0.05). (4) During the 6 months of follow-up, the incidence of MACE in group A was significantly lower than that in group B (P < 0.05).
CONCLUSIONIntracoronary administration of anisodamine is safe and could partly attenuate the no-reflow phenomenon, improve the left ventricular systolic function and synchrony and reduce the incidence of MACE in patients with no-reflow phenomenon post AMI-PCI.
Aged ; Angioplasty, Balloon, Coronary ; methods ; Female ; Humans ; Male ; Middle Aged ; Myocardial Infarction ; physiopathology ; therapy ; Myocardial Reperfusion ; Solanaceous Alkaloids ; administration & dosage ; therapeutic use ; Ventricular Function
10.Study of clinical character and medicinal therapy of viral hepatitis in hospital based on real world.
Yun-ru LI ; Lian-xin WANG ; Yan-ming XIE ; Wei YANG ; Zhuo-yue WANG ; Dan-hui YI ; Yong-yan WANG
China Journal of Chinese Materia Medica 2014;39(18):3448-3453
Viral hepatitis was the most common infectious disease in china. But the diagnosis and treatment were varied because the viral hepatitis patients were hospitalized in different kinds of hospital such as infectious disease hospital, general hospital and Chinese medical hospital. It was necessary to know clinical characters and information of viral hepatitis patients in different hospitals. The general information, subtype distribution, prognosis, complication, medication and relations of onset with solar term from 41 180 viral hepatitis patients based on HIS data were analyzed. It was found that the age of patients between 18 to 59 years old was most; most patients were males. The national basic medical insurance was the most type of payment. The outcome of viral hepatitis in the youth and female were better than that in the old and male. Acute hepatitis was easer to restore than chronic hepatitis. Liver cirrhosis and hepatocellular carcinoma were the two most complications. The peak of onset was during summer solstice, slight heat and great heat. The most common Chinese medicine was Diammonium glycyrrhizinate and the most common western medicine was reduced glutathione. The combination of D. glycyrrhizinate with reduced glutathione, polyene phosphatidylcholine and thymosin was the main pattern. But It was not knew if the combination of western and Chinese medicine was the most effective therapy to protect liver function. It was necessary to take deeply research of the relationship between the combination therapy and their effectiveness.
Adolescent
;
Adult
;
Aged
;
Antiviral Agents
;
therapeutic use
;
Female
;
Glutathione
;
therapeutic use
;
Glycyrrhizic Acid
;
therapeutic use
;
Hepatitis, Viral, Human
;
drug therapy
;
Hospitals
;
Humans
;
Male
;
Middle Aged
;
Young Adult